ANGLE - Re: AGL Stream Log - Read Beaufort Securities's note on...

Read Beaufort Securities's note on ANGLE PLC (AGL), out this morning, by visiting Research Tree: "Ground-breaking potential in detection of cancer, which is now funded to comprehensively demonstrate Parsotix's utility! Parsortix offers the same clinically relevant information from a patient's blood test, irrespective of its location in the body, that otherwise can only be obtained from an invasive metastatic biopsy. Though extensive development and clinical trials will be required across a wide range of indications before such tests to achieve standard international acceptance by medical and insurance providers, much earlier and elementary testing for cancer detection looks set to become a reality. Significantly in this respect, ANGLE differentiates itself from other medtech companies claiming similar abilities. In recent months, the medical world has become aware of a number of new, innovative, but early stage, non-invasive tests (be they derived from blood, saliva, sweat, antibodies etc.) that are apparently also capable of elementary and accurate detection of cancer. The fact remains, however, that detection in the form of a simple 'most probably yes' or 'most probably no' is, in fact, of only limited use unless the test is also capable of capturing or harvesting the same cancer cells for laboratory analysis. Without this, doctors will remain unable to ascertain key information, including identifying the cancer itself along with the extent to which it is aggressive or benign and therefore how to treat it. As such, ANGLE is the only such detection technology that is capable of offering such analysis and so, in Beaufort's opinion, is much more likely to become the globally recommended standard for hospitals and associated medical institutes. Yesterday's news drove this point home. Not only was the Group able to secure major new funding from professional investors in order to progress clinical studies, but it also confirmed a UK contract which allows for routine clinical and research use, itself a key part of the Group's strategy for commercialisation. The funds now available are expected to be sufficient to cover the next 2 years of planned clinical studies, which will be bolstered further by rising research sales. Assuming all goes to plan, ongoing studies of ovarian cancer should have sufficiently concluded to permit first commercial sales to EU hospitals during 1H'2017. Beyond this, FDA authorisation for metastatic breast cancer is expected to be secured through substantive studies defined by three major US-based centres. Successful conclusion here, potentially offers scope for initial North American commercial sales for MBC later in 2017. Further indications, including ovarian and prostate will seek a similar route with the FDA..."